ProCE Banner Activity

CME

Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

Multimedia
In this CME/MOC-certified, on-demand Webcast of a CCO symposium at SABCS 2019, a panel of experts review and discuss evolving strategies for treating HR-positive, HER2-negative advanced breast cancer.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: January 21, 2020

Expiration: January 20, 2021

No longer available for credit.

Share

Faculty

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Eric P. Winer

Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Immunomedics

Lilly

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with HR-positive/HER2-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal treatment strategies for patients with HR+/HER2- advanced breast cancer based on available data, updated clinical guidelines, and expert recommendations
  • Appropriately integrate PI3K/Akt/mTOR and CDK4/6-targeted therapies into clinical practice for optimal personalized medicine for pre-, peri-, and postmenopausal patients with HR+/HER2- breast cancer
  • Manage adverse events associated with multidrug treatment regimens and recognize potential drug–drug interactions to improve patient outcomes
  • Discuss emerging research, the mechanisms of action, and the role of novel therapies and combinations in clinical investigation for patients with HR+/HER2- breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Hope S. Rugo, MD, has disclosed that she has received funds for research support from Amgen, Daiichi, Eisai, Genentech, Immunomedics, Lilly, MacroGenics, Merck, Novartis, OBI, Odonate, Pfizer, and Seattle Genetics and support for travel from Amgen, AstraZeneca, Daiichi, MacroGenics, Merck, Mylan, Pfizer, and Puma.

Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Eric P. Winer, MD, has disclosed that he has received consulting fees from Carrick Therapeutics, Genentech/Roche, Genomic Health, GlaxoSmithKline, Jounce, Leap, Lilly, Merck, and Seattle Genetics and funds for research support from Genentech/Roche and Merck.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 21, 2020, through January 20, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge, confidence, and competence at selecting individualized treatment for patients with hormone receptor–positive breast cancer.